{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:48:01Z","timestamp":1788994081455,"version":"build-2803163510"},"reference-count":0,"publisher":"Clinical Care Targeted Communications Group, LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.37765\/ajmc.2025.89822","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:58:24Z","timestamp":1764089904000},"page":"e322","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness Analysis of Ubrogepant, Rimegepant, and Zavegepant for Acute Migraine Treatment vs Usual Care"],"prefix":"10.37765","volume":"31","member":"24492","published-online":{"date-parts":[[2025,11,18]]},"container-title":["The American Journal of Managed Care"],"original-title":[],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:58:24Z","timestamp":1764089904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajmc.com\/view\/cost-effectiveness-analysis-of-ubrogepant-rimegepant-and-zavegepant-for-acute-migraine-treatment-vs-usual-care"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":0,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.37765\/ajmc.2025.89822","relation":{},"ISSN":["1088-0224","1936-2692"],"issn-type":[{"value":"1088-0224","type":"print"},{"value":"1936-2692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"article-number":"e328"}}